ReviewInternational journal of molecular sciences2025
Cyanobacteria-Derived Extracellular Vesicles: A Novel Frontier in Drug Delivery and Therapeutics.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cyanobacteria, known for their diverse and potent bioactive compounds, present a unique method for drug delivery via their extracellular vesicles (EVs), often described as exosome-like due to size and function but distinct in biogenesis. These naturally occurring vesicles, particularly those from cyanobacteria, are gaining attention as potential carriers for targeted drug delivery because of their biocompatibility, stability, and ability to encapsulate various bioactive compounds. However, cyanobacterial EVs remain underexplored as a dedicated nanocarrier platform, and their specific advantages and limitations relative to existing systems have not been systematically synthesized. This review explores the potential therapeutic uses of cyanobacterial EVs, emphasizing their roles in cancer treatment, antimicrobial therapies, neuroprotection, and immune modulation. We explore their biogenesis and structural features, comparing them to synthetic nanocarriers like polymeric nanoparticles and liposomes. The review also addresses the challenges of isolating and characterizing cyanobacterial EVs at scale and highlights the need for advancements in synthetic biology and genetic engineering to optimize their therapeutic potential. Despite these challenges, cyanobacterial EVs' unique properties offer significant promise for advancing drug delivery systems and providing innovative solutions for treating complex diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.